
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.
Lauren Schoukroun-Barnes, PhD, is associate manager of Regulatory Affairs, Sia/LBG.
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.